RxDoctor Payments Data

Fernando Garcia, MD

Internal Medicine · Marksville, LANPI 1992707236

Payments from drug & device makers

$1,087in general payments, 2019–2025

Across 56 payments — averaging $19.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$185
  • Novo Nordisk$148
  • GSK$74
  • Lilly USA, LLC$57
  • Novartis$53
  • Merck$51
  • plus $520 from 19 others

What the payments were for

  • Food & beverage$1,07299%
  • Education$151%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,087 in reported general payments places this provider in the 65th percentile of 1,528 internal medicine providers in Louisiana.

See all internal medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$12,363
Medicare patients
29
Services billed
169

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide84$92,799
EliquisApixaban209$79,260
TrulicityDulaglutide68$76,283
JardianceEmpagliflozin121$73,883
MounjaroTirzepatide41$53,321
Trelegy ElliptaFluticasone/Umeclidin/Vilanter75$49,646
LinzessLinaclotide22$12,397
XareltoRivaroxaban16$8,132
Sucralfate55$7,768
TradjentaLinagliptin12$6,982
PremarinEstrogens, Conjugated19$4,735
Lantus SolostarInsulin Glargine,hum.Rec.Anlog41$4,572
GemtesaVibegron19$4,536
Atorvastatin Calcium313$4,424
Gabapentin267$4,256

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$57$129,604109 claims
Novo NordiskOzempic$148$92,79984 claims
PfizerEliquis, Premarin$14$83,994228 claims
Boehringer IngelheimJardiance, Tradjenta$27$80,866133 claims
GSKTrelegy Ellipta$74$49,64675 claims
AbbVieLinzess$185$12,39722 claims
AstraZenecaNexium$22$3,48213 claims
Astellas Pharma US IncMyrbetriq$35$3,16714 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 1,528 internal medicine providers in Louisiana.

Other internal medicine in Marksville

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →